Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Milan
Treatments:Biologic therapyHospital:Istituto di Ricovero e Cura a Carattere Scientifico
Drugs:Journal:Link
Date:Jun 2014

Description:

Patients:
This phase 3 study involved 134 non-small cell lung cancer patients who had progressed following, or were deemed refractory to, platinum-based chemotherapy. The median patient age was 66 years and 74% were male.

Treatment:
Patients were treated with the biologic erlotinib, a tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities were grade 4 diarrhea and skin reactions.

Results:
The median overall survival was 7.7 months.

Support:
This study was partially supported by Biodesix, a molecular diagnostics company that does not manufacture cancer drugs.

Correspondence: Dr. Vanesa Gregorc; email: [email protected]



Back